Back to Search Results
Image Place holder

Sarah Hoffe, MD

★★★★★
★★★★★
4.9 (119 ratings)
Specialty: Radiation Oncology
Program: Radiation Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Adrenal Carcinoma, Anal Cancer, Appendiceal (Appendix) Cancer, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, GIST (Gastrointestinal Stromal Tumor), Liver Cancer, Pancreatic Cancer, Rectal Cancer

Dr. Sarah Hoffe is the Section Head of GI Radiation Oncology at Moffitt Cancer Center and joined the faculty in 2006. She is a Senior Member at Moffitt and Professor in the University Of South Florida Morsani College Of Medicine’s Department of Oncologic Sciences. Dr. Hoffe’s research and clinical interests include cancers of the esophagus, stomach, liver, pancreas, bile duct, rectum, colon, anus, as well as neuroendocrine cancers. She has experience with advanced radiation therapy techniques such as intensity modulated radiation therapy (IMRT), three dimensional conformal radiation therapy (3D-CRT), stereotactic body radiation therapy (SBRT), radioembolization, and image guided radiation therapy (IGRT) using endoscopically implanted fiducial markers. At Moffitt, she works closely with her multidisciplinary colleagues including GI surgeons, medical oncologists, gastroenterologists, radiologists and pathologists to develop new treatments for patients with GI cancers. She is very interested in 4D PET/CT imaging and works with the PET/CT committee at Moffitt  In addition to GI cancers and radiation oncology, Dr. Hoffe is also interested in the integration of novel patient engagement technologies that will improve the patient experience, such as piloting novel virtual reality tools. After completing her undergraduate studies at Brown University, Dr. Hoffe received her MD degree from the University of Vermont.  She then completed a transitional year internship at Mayo Clinic Jacksonville followed by residency in radiation oncology at Duke University Medical Center and Memorial Sloan-Kettering Cancer Center and fellowship at MD Anderson Cancer Center.   Dr. Hoffe devotes a significant portion of her time to the promotion of medical education. Nationally, she is the Director of eContouring at ASTRO, is on the advisory board for the Contemporary Radiation Oncology Journal, and is a contributor to the Up to Date Online educational site, having co-authored the section on bone metastases. She serves on the ASTRO Education Committee and the HIMSS connected patient committee. Locally, she is on the Editorial Board of Cancer Control Journal and is active at the USF Morsani College of Medicine where she is a coach for the SELECT program and the leadership competency co-director. In 2009, Dr. Hoffe was the first radiation oncologist at Moffitt to be selected as the Physician of the Year.


Education & Training

Fellowship:

  • University of Texas MD Anderson Cancer Center - Radiation Oncology

Residency:

  • Duke University Medical Center - Radiation Oncology
  • Memorial Sloan Kettering Cancer Center - Radiation Oncology

Medical School:

  • University of Vermont - MD
Awards
Start Year: 2009 End Year: 2009 Physician of the Year, Sponsor: H. Lee Moffitt Cancer Center & Research Institute
Video Profile
Participating Trials

CLINICAL TRIAL 21038
GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
Condition: Gastrointestinal Tumor
Intervention: FOLFIRINOX (); GC4711/Placebo (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Taxol (paclitaxel); cisplatin (); gemcitabine (); paclitaxel ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kis B, Shridhar R, Mhaskar R, Gyano M, Frakes JM, El-Haddad G, Choi J, Kim RD, Hoffe SE. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma - A Prospective Feasibility Study. J Vasc Interv Radiol. 2023 May. Pubmedid: 37210030.
  • Bryant JM, Palm RF, Herrera R, Rubens M, Hoffe SE, Kim DW, Kaiser A, Ucar A, Fleming J, De Zarraga F, Hodul P, Aparo S, Asbun H, Malafa M, Jimenez R, Denbo J, Frakes JM, Chuong MD. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART). Cancer Control. 2023 Jan.30. Pubmedid: 36598464.
  • Eshmuminov D, Aminjonov B, Palm RF, Malleo G, Schmocker RK, Abdallah R, Yoo C, Shaib WL, Schneider MA, Rangelova E, Choi YJ, Kim H, Rose JB, Patel S, Wilson GC, Maloney S, Timmermann L, Sahora K, Rössler F, Lopez-Lopez V, Boyer E, Maggino L, Malinka T, Park JY, Katz MHG, Prakash L, Ahmad SA, Helton S, Jang JY, Hoffe SE, Salvia R, Taieb J, He J, Clavien PA, Held U, Lehmann K. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Ann Surg Oncol. 2023 Apr. Pubmedid: 37020094.
  • Eshmuminov D, Aminjonov B, Palm RF, Malleo G, Schmocker RK, Abdallah R, Yoo C, Shaib WL, Schneider MA, Rangelova E, Choi YJ, Kim H, Rose JB, Patel S, Wilson GC, Maloney S, Timmermann L, Sahora K, Rössler F, Lopez-Lopez V, Boyer E, Maggino L, Malinka T, Park JY, Katz MHG, Prakash L, Ahmad SA, Helton S, Jang JY, Hoffe SE, Salvia R, Taieb J, He J, Clavien PA, Held U, Lehmann K. ASO Visual Abstract: FOLFIRINOX or Gemcitabine Based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-Institutional, Patient-Level Meta-Analysis and Systematic Review. Ann Surg Oncol. 2023 Apr. Pubmedid: 37067744.
  • Pointer DT, McDonald JA, Naffouje SA, Mehta R, Fleming JB, Fontaine JP, Lauwers GY, Frakes JM, Hoffe SE, Pimiento JM. The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer. J Surg Oncol. 2022 Sep.126(3):465-478. Pubmedid: 35578777. Pmcid: PMC9339510.
  • Bibok A, Kis B, Frakes J, Hoffe S, Zhang J, Jain R, Parikh N. Yttrium-90 Radioembolization for Liver-Dominant Metastatic Prostate Cancer: A Case Series. J Vasc Interv Radiol. 2022 Sep.33(9):1061-1065. Pubmedid: 36049841.
  • Kumar P, Mhaskar R, Kim R, Anaya D, Frakes J, Hoffe S, Choi J, Kis B. Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres. J Clin Exp Hepatol. 2022 Sep.12(5):1259-1263. Pubmedid: 36157145. Pmcid: PMC9499841.
  • Song EY, Chuang J, Frakes JM, Dilling T, Quinn JF, Rosenberg S, Johnstone P, Harrison L, Hoffe SE. Developing a Dedicated Leadership Curriculum for Radiation Oncology Residents. J Cancer Educ. 2022 Oct.37(5):1446-1453. Pubmedid: 33619686.
  • Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2022 Oct.20(10):1139-1167. Pubmedid: 36240850.
  • Bryant JM, Palm RF, Liveringhouse C, Boyer E, Hodul P, Malafa M, Denbo J, Kim D, Carballido E, Fleming JB, Hoffe S, Frakes J. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). Adv Radiat Oncol. 2022 Nov.7(6):101045. Pubmedid: 36420193. Pmcid: PMC9677195.
  • Pointer DT, Saeed S, Naffouje SA, Mehta R, Hoffe SE, Dineen SP, Fleming JB, Fontaine JP, Pimiento JM. Outcomes of 350 Robotic-assisted Esophagectomies at a High-volume Cancer Center: A Contemporary Propensity-score Matched Analysis. Ann Surg. 2022 Jul.276(1):111-118. Pubmedid: 33201093.
  • Sim AJ, Hoffe SE, Latifi K, Palm RF, Feygelman V, Leuthold S, Dookhoo M, Dennett M, Rosenberg SA, Frakes JM. A Practical Workflow for Magnetic Resonance-Guided Stereotactic Body Radiation Therapy to the Pancreas. Pract Radiat Oncol. 2022 Jul.13(1):e45-e53. Pubmedid: 35901947.
  • Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 Feb.26(2):376-386. Pubmedid: 34506031.
  • Naffouje SA, Manguso N, Imanirad I, Sahin IH, Xie H, Hoffe S, Frakes J, Sanchez J, Dessureault S, Felder S. Neoadjuvant rectal score is prognostic for survival: A population-based propensity-matched analysis. J Surg Oncol. 2022 Dec.126(7):1219-1231. Pubmedid: 35916542.
  • Mills MN, Naz A, Sanchez J, Dessureault S, Imanirad I, Lauwers G, Moore M, Hoffe S, Frakes J, Felder S. Rectal tumor fragmentation as a response pattern following chemoradiation. J Gastrointest Oncol. 2022 Dec.13(6):2951-2962. Pubmedid: 36636056. Pmcid: PMC9830359.
  • Mehta R, Frakes J, Kim J, Nixon A, Liu Y, Howard L, Martinez Jimenez ME, Carballido E, Imanirad I, Sanchez J, Dessureault S, Xie H, Felder S, Sahin I, Hoffe S, Malafa M, Kim R. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist. 2022 Aug.27(8):621-e617. Pubmedid: 35325225. Pmcid: PMC9355805.
  • Wood AC, Zhang Y, Mo Q, Cen L, Fontaine J, Hoffe SE, Frakes J, Dineen SP, Pimiento JM, Walko CM, Mehta R. Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. Oncologist. 2022 Apr.27(4):307-313. Pubmedid: 35380714. Pmcid: PMC8982441.
  • Allen CJ, Pointer DT, Blumenthaler AN, Mehta RJ, Hoffe SE, Minsky BD, Smith GL, Blum M, Mansfield PF, Ikoma N, Das P, Ajani J, Dineen SP, Fleming JB, Badgwell BD, Pimiento JM. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 Oct.274(4):544-548. Pubmedid: 34132693. Pmcid: PMC8988446.
  • Barakat E, Bibok A, Rishi A, Ahmed A, Frakes JM, Hoffe SE, Armaghani AJ, Soyano AE, Costa RLB, El-Haddad G, Choi J, Kis B. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study. Adv Radiat Oncol. 2021 Oct.7(1):100838. Pubmedid: 35071835. Pmcid: PMC8767250.
  • Bibok A, Mhaskar R, Jain R, Zhang J, Frakes J, Hoffe S, El-Haddad G, Parikh N, Ahmed A, Fishman MN, Choi J, Kis B. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study. Cardiovasc Intervent Radiol. 2021 Nov.44(11):1755-1762. Pubmedid: 34312688.
  • Felder SI, Feuerlein S, Parsee A, Imanirad I, Sanchez J, Dessureault S, Kim R, Hoffe S, Frakes J, Costello J. Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples. Abdom Radiol (NY). 2021 May.46(5):1783-1804. Pubmedid: 33111189.
  • Bigness A, Imanirad I, Sahin IH, Xie H, Frakes J, Hoffe S, Laskowitz D, Felder S. Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation. CA-Cancer J Clin. 2021 May.71(3):198-208. Pubmedid: 33592118.
  • McDonald J, Chuang CY, Hicks JK, Berry DK, Imanirad I, Rishi A, Frakes JM, Hoffe SE, Felder S. FANCD2 Mutation in a Patient With Early Rectal Cancer Receiving Definitive Chemoradiation. Adv Radiat Oncol. 2021 May.6(5):100717. Pubmedid: 34258475. Pmcid: PMC8260782.
  • Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Mar.19(3):329-359. Pubmedid: 33724754.
  • Dalsania RM, Shah KP, Stotsky-Himelfarb E, Hoffe S, Willingham FF. Management of Long-Term Toxicity From Pelvic Radiation Therapy. Am Soc Clin Oncol Educ Book. 2021 Mar.41:1-11. Pubmedid: 33793314.
  • Dohm A, Sanchez J, Stotsky-Himelfarb E, Willingham FF, Hoffe S. Strategies to Minimize Late Effects From Pelvic Radiotherapy. Am Soc Clin Oncol Educ Book. 2021 Mar.41:158-168. Pubmedid: 34010045.
  • Hutchinson T, Hoffe S, Saeed S, Pflanzer SA, Fleming JB, Pabbathi S. Gastrointestinal Disease-Specific Survivorship Care: A New Personalized Model Integrating Onco-Wellness. Cancer Control. 2021 Jan.28. Pubmedid: 33926264. Pmcid: PMC8204645.
  • Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel). 2021 Feb.13(3). Pubmedid: 33540736. Pmcid: PMC7867245.
  • Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
  • Tomaszewski MR, Latifi K, Boyer E, Palm RF, El Naqa I, Moros EG, Hoffe SE, Rosenberg SA, Frakes JM, Gillies RJ. Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Radiat Oncol. 2021 Dec.16(1):237. Pubmedid: 34911546. Pmcid: PMC8672552.
  • Saeed SM, Naffouje S, Mehta R, Hoffe SE, Fontaine JP, Lauwers GY, Shah P, Frakes J, Pimiento JM. Impact of histology classification on pathologic treatment response and overall survival in distal esophageal cancer patients: a propensity matched analysis. Dis Esophagus. 2021 Aug.34(8). Pubmedid: 32996568.
  • Sim AJ, Frakes JM, Hoffe SE, Wuthrick E, Dilling TJ, Rosenberg S. Novel MR-Guided Radiotherapy Elective Rotation for Radiation Oncology Trainees. Cureus. 2020 Sep.12(9):e10706. Pubmedid: 33133871. Pmcid: PMC7594659.
  • Yuan Z, Frazer M, Ahmed KA, Naqvi SMH, Schell MJ, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Torres-Roca JF, Hoffe SE, Frakes JM. Modeling precision genomic-based radiation dose response in rectal cancer. Future Oncol. 2020 Oct.16(30):2411-2420. Pubmedid: 32686956.
  • Schumacher LD, Dal Pra A, Hoffe SE, Mellon EA. Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. Br J Radiol. 2020 Oct.93(1114):20200028. Pubmedid: 32783629. Pmcid: PMC7548359.
  • Frazer ML, Yang G, Felder S, McDonald J, Sanchez J, Dessureault S, Imanirad I, Carballido E, Kim RD, Hoffe SE, Frakes JM. Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation. Am J Clin Oncol. 2020 May.43(5):319-324. Pubmedid: 32028341.
  • Yuan Z, Frazer M, Zhang GG, Latifi K, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Frakes JM. CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study. J Med Imaging Radiat Oncol. 2020 Jun.64(3):444-449. Pubmedid: 32386109.
  • Song EY, Frakes JM, Extermann M, Klocksieben F, Mehta R, Saeed S, Hoffe SE, Pimiento JM. Clinical Factors and Outcomes of Octogenarians Receiving Curative Surgery for Esophageal Cancer. J Surg Res. 2020 Jul.251:100-106. Pubmedid: 32114211.
  • Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Ne. 2020 Jul.18(7):806-815. Pubmedid: 32634771.
  • Bhutani MS, Klapman JB, Tuli R, El-Haddad G, Hoffe S, Wong FCL, Chasen B, Fogelman DR, Lo SK, Nissen NN, Hendifar AE, Varadhachary G, Katz MHG, Erwin WD, Koay EJ, Tamm EP, Singh BS, Mehta R, Wolff RA, Soman A, Cazacu IM, Herman JM. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endosc Ultrasound. 2020 Jan.9(1):24-30. Pubmedid: 31670288. Pmcid: PMC7038730.
  • Palm RF, Hoffe SE. Increasing Incidence and Knowledge Gaps Within a Clinical Challenge: Understanding the Paradox and Complexities of Young-Onset Colorectal Cancer. JCO Oncol Pract. 2020 Jan.16(1):28-29. Pubmedid: 32039663.
  • Sim AJ, Redler G, Peacock J, Naso C, Wasserman S, McNitt KB, Hoffe SE, Johnstone PAS, Harrison LB, Rosenberg SA. Harnessing COVID-Driven Technical Innovations for Improved Multi-Disciplinary Cancer Care in the Post-COVID Era: The Virtual Patient Room. Cancer Control. 2020 Jan.27(1). Pubmedid: 33023342. Pmcid: PMC7791470.
  • Tchelebi LT, Romesser PB, Feuerlein S, Hoffe S, Latifi K, Felder S, Chuong MD. Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management. Cancer Control. 2020 Jan.27(1). Pubmedid: 33118384. Pmcid: PMC7791447.
  • Mitin T, Degnin C, Chen Y, Shirvani S, Gillespie E, Hoffe S, Latifi K, Nabavizadeh N, Dengina N, Chernich M, Usychkin S, Kharitonova E, Egorova Y, Pankratov A, Tsimafeyeu I, Thomas CR, Tjulandin S, Likhacheva A. Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise. J Cancer Educ. 2020 Feb.35(1):105-111. Pubmedid: 30467774.
  • Figura NB, Oliver DE, Mohammadi H, Martinez K, Grass GD, Hoffe SE, Johnstone PAS, Frakes JM. Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution Experience. Am J Clin Oncol. 2020 Feb.43(2):107-114. Pubmedid: 31764023.
  • Parsee AA, McDonald JA, Jiang K, Latifi K, Mehta R, Frakes JM, Pimiento JM, Hoffe SE. Radiation-induced hepatitis masquerading as metastatic disease: the importance of correlating diagnostic imaging with treatment planning. J Gastrointest Oncol. 2020 Feb.11(1):133-138. Pubmedid: 32175116. Pmcid: PMC7052759.
  • Song EY, Venkat P, Fradley M, Frakes JM, Klocksieben F, Fontaine J, Mehta R, Saeed S, Hoffe SE, Pimiento JM. Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgery. J Gastrointest Oncol. 2020 Feb.11(1):68-75. Pubmedid: 32175107. Pmcid: PMC7052762.
  • Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, Tomaszewski MR, Latifi K, Pimiento JM, Fontaine JP, Mehta R, Harrison LB, Hoffe SE, Frakes JM. Pretreatment CT and 18 F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer. J Med Imaging Radiat Oncol. 2020 Dec.65(1):102-111. Pubmedid: 33258556.
  • Hoffe S, Frakes JM, Aguilera TA, Czito B, Palta M, Brookes M, Schweizer C, Colbert L, Moningi S, Bhutani MS, Pant S, Tzeng CW, Tidwell RS, Thall P, Yuan Y, Moser EC, Holmlund J, Herman J, Taniguchi CM. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). Int J Radiat Oncol Biol Phys. 2020 Dec.108(5):1399-1400. Pubmedid: 33427657.
  • Palta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N, Parekh A, Patton C, Pepek JM, Salama JK, Tuli R, Koong AC. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2019 Sep.9(5):322-332. Pubmedid: 31474330.
  • Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2019 Sep.17(9):1109-1133. Pubmedid: 31487687.
  • Wang J, Zhang H, Chuong M, Latifi K, Tan S, Choi W, Hoffe S, Shridhar R, Lu W. Prediction of Anal Cancer Recurrence After Chemoradiotherapy Using Quantitative Image Features Extracted From Serial 18F-FDG PET/CT. Front Oncol. 2019 Sep.9:934. Pubmedid: 31612104. Pmcid: PMC6777412.
  • Song E, Segarra D, Latifi K, Leuthold S, Belinc D, Pena L, Malafa M, Frakes JM, Hoffe SE. Recognition of Tumor Invasion of a Pancreatic Head Biliary Stent During Stereotactic Body Radiation Therapy. Pract Radiat Oncol. 2019 May.9(3):132-135. Pubmedid: 30708132.
  • Chuong MD, Kaiser A, Khan F, Parikh P, Ben-Josef E, Crane C, Brunner T, Okumura T, Schreuder N, Bentzen SM, Gutierrez A, Mendez Romero A, Yoon SM, Sharma N, Kim TH, Kishi K, Moeslein F, Hoffe S, Schefter T, Hanish S, Scorsetti M, Apisarnthanarax S. Consensus Report From the Miami Liver Proton Therapy Conference. Front Oncol. 2019 May.9:457. Pubmedid: 31214502. Pmcid: PMC6557299.
  • Felder SI, Hoffe SE. Redefining Rectal Cancer Priorities Through a Watch-and-Wait Paradigm: Balancing Cancer Cure and Quality of Life. J Oncol Pract. 2019 Mar.15(3):135-136. Pubmedid: 30861366.
  • Machicado JD, Obuch JC, Goodman KA, Schefter TE, Frakes J, Hoffe S, Latifi K, Simon VC, Santangelo T, Ezekwe E, Edmundowicz SA, Brauer BC, Shah RJ, Hammad HT, Wagh MS, Attwell A, Han S, Klapman J, Wani S. Endoscopic Ultrasound Placement of Preloaded Fiducial Markers Shortens Procedure Time Compared to Back-Loaded Markers. Clin Gastroenterol H. 2019 Dec.17(13):2749-2758.e2. Pubmedid: 31042578.
  • Saeed SM, Fontaine JP, Dam AN, Hoffe SE, Cameron M, Frakes J, Mehta R, Gurd E, Pimiento JM. Is Preoperative G-Tube Use Safe for Esophageal Cancer Patients?. J Am Coll Nutr. 2019 Aug.39(4):301-306. Pubmedid: 31397638.
  • Mohammadi H, Abuodeh Y, Jin W, Frakes J, Friedman M, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Hoffe S. Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol. 2018 Oct.9(5):840-846. Pubmedid: 30505583. Pmcid: PMC6219966.
  • Orcutt ST, Abuodeh Y, Naghavi A, Frakes J, Hoffe S, Kis B, Anaya DA. Kinetic analysis of contralateral liver hypertrophy after radioembolization of primary and metastatic liver tumors. Surgery. 2018 May.163(5):1020-1027. Pubmedid: 29325784.
  • Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. Am J Clin Oncol. 2018 Mar.41(3):254-258. Pubmedid: 26703814. Pmcid: PMC7810133.
  • Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Am J Clin Oncol. 2018 Mar.41(3):236-241. Pubmedid: 26796313.
  • Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. J Gastrointest Oncol. 2018 Jun.9(3):546-552. Pubmedid: 29998020. Pmcid: PMC6006034.
  • Jin WH, Hoffe SE, Shridhar R, Strom T, Venkat P, Springett GM, Hodul PJ, Pimiento JM, Meredith KL, Malafa MP, Frakes JM. Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail. J Gastrointest Oncol. 2018 Jun.9(3):487-494. Pubmedid: 29998014. Pmcid: PMC6006031.
  • Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Jul.16(7):874-901. Pubmedid: 30006429.
  • Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Jul.16(7):852-871. Pubmedid: 30006428.
  • Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol. 2018 Feb.117(2):150-159. Pubmedid: 28833197. Pmcid: PMC7771345.
  • Jin WH, Mellon EA, Frakes JM, Murimwa GZ, Hodul PJ, Pimiento JM, Malafa MP, Hoffe SE. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. J Gastrointest Oncol. 2018 Feb.9(1):24-34. Pubmedid: 29564168. Pmcid: PMC5848029.
  • Yang GQ, Mhaskar R, Rishi A, Naghavi AO, Frakes JM, Almhanna K, Fontaine J, Pimiento JM, Hoffe SE. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy. Dis Esophagus. 2018 Dec.32(8). Pubmedid: 30597022.
  • Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2018 Aug.29(8):1101-1108. Pubmedid: 30042074. Pmcid: PMC7771272.
  • Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Ne. 2018 Apr.16(4):359-369. Pubmedid: 29632055.
  • Saeed N, Shridhar R, Almhanna K, Hoffe S, Chuong M, Meredith K. CT-based assessment of visceral adiposity and outcomes for esophageal adenocarcinoma. J Gastrointest Oncol. 2017 Oct.8(5):833-841. Pubmedid: 29184687. Pmcid: PMC5674266.
  • Saeed NA, Mellon EA, Meredith KL, Hoffe SE, Shridhar R, Frakes J, Fontaine JP, Pimiento JM, Kothari N, Almhanna K. Adjuvant chemotherapy and outcomes in esophageal carcinoma. J Gastrointest Oncol. 2017 Oct.8(5):816-824. Pubmedid: 29184685. Pmcid: PMC5674263.
  • Murimwa GZ, Venkat PS, Jin W, Leuthold S, Latifi K, Almhanna K, Pimiento JM, Fontaine JP, Hoffe SE, Frakes JM. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol. 2017 Oct.8(5):808-815. Pubmedid: 29184684. Pmcid: PMC5674260.
  • Frakes J, Mellon EA, Springett GM, Hodul P, Malafa MP, Fulp WJ, Zhao X, Hoffe SE, Shridhar R, Meredith KL. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. J Gastrointest Oncol. 2017 Oct.8(5):758-765. Pubmedid: 29184679. Pmcid: PMC5674250.
  • Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017 Mar.56(3):391-397. Pubmedid: 27885876.
  • Oliver JA, Venkat P, Frakes JM, Klapman J, Harris C, Montilla-Soler J, Dhadham GC, Altazi BA, Zhang GG, Moros EG, Shridhar R, Hoffe SE, Latifi K. Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer. Endosc Int Open. 2017 Jun.5(6):E496-E504. Pubmedid: 28573183. Pmcid: PMC5451282.
  • Venkat PS, Shridhar R, Naghavi AO, Hoffe SE, Almhanna K, Pimiento JM, Fontaine JP, Abuodeh Y, Meredith KL, Frakes JM. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer. Dis Esophagus. 2017 Jul.30(7):1-9. Pubmedid: 30052899.
  • Salem AI, Thau MR, Strom TJ, Abbott AM, Saeed N, Almhanna K, Hoffe SE, Shridhar R, Karl RC, Meredith KL. Effect of body mass index on operative outcome after robotic-assisted Ivor-Lewis esophagectomy: retrospective analysis of 129 cases at a single high-volume tertiary care center. Dis Esophagus. 2017 Jan.30(1):1-7. Pubmedid: 27149640.
  • Zhang DG, Feygelman V, Moros EG, Latifi K, Hoffe S, Frakes J, Zhang GG. Superficial and peripheral dose in compensator-based FFF beam IMRT. J Appl Clin Med Phys. 2017 Jan.18(1):151-156. Pubmedid: 28291940. Pmcid: PMC5689887.
  • Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2017 Feb.28(2):254-259. Pubmedid: 27955832. Pmcid: PMC7771309.
  • Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP. Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?. World J Gastroenterol. 2017 Dec.23(46):8193-8199. Pubmedid: 29290655. Pmcid: PMC5739925.
  • Bustamante L, Frakes J, Hoffe S, Kim R. Investigational drugs for treating anal cancer and future perspectives. Expert Opin Inv Drug. 2016 Sep.25(1):51-62. Pubmedid: 26560877.
  • Kis B, Mills M, Hoffe SE. Hepatic radioembolization from transradial access: initial experience and comparison to transfemoral access. Diagn Interv Radiol. 2016 Sep.22(5):444-449. Pubmedid: 27353460. Pmcid: PMC5019848.
  • Prithviraj GK, Baksh K, Fulp W, Meredith K, Hoffe S, Shridhar R, Almhanna K. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2016 Oct.28(8):782-787. Pubmedid: 25155802.
  • Jin W, Mellon EA, Hoffe SE, Frakes JM, Springett GM, Centeno BA, Kim R, Mahipal A, Pimiento JM, Malafa MP, Latifi K. Does Metabolic Tumor Volume Predict Tumor Regression Grade After Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer?. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E195. Pubmedid: 27674030.
  • Mohammadi H, Abuodeh YA, Jin W, Frakes JM, Friedman M, Biebel B, Choi J, El-Haddad GE, Kis B, Sweeney J, Kim R, Pimiento JM, Malafa MP, Anaya D, Hoffe SE. Using the ALBI Grade as a Prognostic Marker for Radioembolization of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E194-E195.
  • Mellon EA, Hoffe SE, Frakes JM, Strom T, Springett GM, Shridhar R, Centeno BA, Malafa MP, Chuong MD, Hodul PJ. Predictors and Survival for Pathologic Tumor Response Grade in Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Induction Chemotherapy and Neoadjuvant Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E165. Pubmedid: 27673949.
  • Pearson AL, Jin W, Mellon EA, Frakes JM, Strom T, Springett GM, Kim R, Mahipal A, Hodul PJ, Pimiento JM, Shridhar R, Malafa MP, Hoffe SE. Post-Stereotactic Body Radiation Therapy (SBRT) Neutrophil-to-Lymphocyte Ratio (NLR) in Patients With Borderline Resectable Pancreatic Cancer (BRPC) May Be a Prognostic Biomarker. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E153. Pubmedid: 27673917.
  • Glazer ES, Neill KG, Frakes JM, Coppola D, Hodul PJ, Hoffe SE, Pimiento JM, Springett GM, Malafa MP. Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. Cancer Control. 2016 Oct.23(4):446-454. Pubmedid: 27842335.
  • Dhadham GC, Hoffe S, Harris CL, Klapman JB. Endoscopic ultrasound-guided fiducial marker placement for image-guided radiation therapy without fluoroscopy: safety and technical feasibility. Endosc Int Open. 2016 Mar.4(3):E378-E382. Pubmedid: 27004258. Pmcid: PMC4798935.
  • Almhanna K, Weber J, Shridhar R, Hoffe S, Strosberg J, Meredith K. Determining the optimal number of lymph nodes harvested during esophagectomy. J Gastrointest Oncol. 2016 Jun.7(3):387-394. Pubmedid: 27284471. Pmcid: PMC4880760.
  • Kucera S, Barthel J, Klapman J, Shridhar R, Hoffe S, Harris C, Almhanna K, Meredith K. Small caliber covered self-expanding metal stents in the management of malignant dysphagia. J Gastrointest Oncol. 2016 Jun.7(3):411-419. Pubmedid: 27284474. Pmcid: PMC4880758.
  • Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016 Feb.118(2):382-386. Pubmedid: 26861740. Pmcid: PMC7771531.
  • Srikumar T, Markow M, Centeno B, Hoffe S, Tao J, Fernandez H, Strosberg J, Shibata D. Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. Curr Oncol. 2016 Feb.23(1):e70-e74. Pubmedid: 26966416. Pmcid: PMC4754072.
  • Permuth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M, On Behalf Of The Florida Pancreas Collaborative . Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016 Dec.7(52):85785-85797. Pubmedid: 27589689. Pmcid: PMC5349874.
  • Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol. 2016 Dec.22(47):10406-10414. Pubmedid: 28058021. Pmcid: PMC5175253.
  • Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM, Eschrich SA, Torres-Roca JF. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Aug.95(5):1399-1404. Pubmedid: 27319288. Pmcid: PMC7771381.
  • Kothari N, Mellon E, Hoffe SE, Frakes J, Shridhar R, Pimiento J, Meredith K, Tran ND, Saeed N, Almhanna K. Outcomes in patients with brain metastasis from esophageal carcinoma. J Gastrointest Oncol. 2016 Aug.7(4):562-569. Pubmedid: 27563446. Pmcid: PMC4963374.
  • Mellon EA, Strom TJ, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. J Gastrointest Oncol. 2016 Aug.7(4):547-555. Pubmedid: 27563444. Pmcid: PMC4963371.
  • Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Ann Surg Oncol. 2016 Apr.23(4):1371-1379. Pubmedid: 26661409.
  • Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL. AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. J Gastrointest Oncol. 2016 Apr.7(2):158-165. Pubmedid: 27034781. Pmcid: PMC4783740.
  • Shridhar R, Abbott AM, Doepker M, Hoffe SE, Almhanna K, Meredith KL. Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy. J Gastrointest Oncol. 2016 Apr.7(2):206-212. Pubmedid: 27034787. Pmcid: PMC4783744.
  • Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol. 2016 Apr.7(2):221-227. Pubmedid: 27034789. Pmcid: PMC4783738.
  • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Sep.14(3):146-153. Pubmedid: 25795047.
  • Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Cancer. 2015 Sep.46(3):284-290. Pubmedid: 26018826.
  • Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother Oncol. 2015 Oct.117(1):159-164. Pubmedid: 26235848. Pmcid: PMC7771365.
  • Balducci L, Dolan D, Hoffe SA. Palliative Care in Older Patients With Cancer. Cancer Control. 2015 Oct.22(4):480-488. Pubmedid: 26678975.
  • Hayman TJ, Strom T, Springett GM, Balducci L, Hoffe SE, Meredith KL, Hodul P, Malafa M, Shridhar R. Outcomes of resected pancreatic cancer in patients age ≥70. J Gastrointest Oncol. 2015 Oct.6(5):498-504. Pubmedid: 26487943. Pmcid: PMC4570916.
  • Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015 Oct.7(10):241-249. Pubmedid: 26483878. Pmcid: PMC4606178.
  • Strom TJ, Klapman JB, Springett GM, Meredith KL, Hoffe SE, Choi J, Hodul P, Malafa MP, Shridhar R. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Surg Endosc. 2015 Nov.29(11):3273-3281. Pubmedid: 25631110. Pmcid: PMC4918460.
  • Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol. 2015 Nov.112(6):597-602. Pubmedid: 26394724.
  • Freilich J, Hoffe SE, Almhanna K, Dinwoodie W, Yue B, Fulp W, Meredith KL, Shridhar R. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus. 2015 May.28(4):352-357. Pubmedid: 24635657.
  • Frakes JM, Strom T, Springett GM, Hoffe SE, Balducci L, Hodul P, Malafa MP, Shridhar R. Resected pancreatic cancer outcomes in the elderly. Geriatr Oncol. 2015 Mar.6(2):127-132. Pubmedid: 25555451.
  • Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul.54(7):979-985. Pubmedid: 25734581.
  • Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF. Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. Int J Radiat Oncol Biol Phys. 2015 Jul.92(4):837-842. Pubmedid: 25838188. Pmcid: PMC4481172.
  • Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist. 2015 Feb.20(2):134-142. Pubmedid: 25561508. Pmcid: PMC4319638.
  • Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015 Feb.6(1):39-44. Pubmedid: 25642336. Pmcid: PMC4294830.
  • Abbott A, Shridhar R, Hoffe S, Almhanna K, Doepker M, Saeed N, Meredith K. Robotic assisted Ivor Lewis esophagectomy in the elderly patient. J Gastrointest Oncol. 2015 Feb.6(1):31-38. Pubmedid: 25642335. Pmcid: PMC4294822.
  • Almhanna K, Hoffe S. Esophageal cancer 2015, more questions than answers. J Gastrointest Oncol. 2015 Feb.6(1):1-2. Pubmedid: 25642332. Pmcid: PMC4294825.
  • Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2014 Sep.18(9):1013-1021. Pubmedid: 23966224. Pmcid: PMC3780633.
  • Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. Ann Surg Oncol. 2014 Nov.21(12):3744-3750. Pubmedid: 24854492.
  • Kunkler IH, Audisio R, Belkacemi Y, Betz M, Gore E, Hoffe S, Kirova Y, Koper P, Lagrange JL, Markouizou A, Pfeffer R, Villa S. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol. 2014 Nov.25(11):2134-2146. Pubmedid: 24625455.
  • Chuong MD, Fernandez DC, Shridhar R, Hoffe SE, Saini A, Hunt D, Meredith KL, Biagioli MC. High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients. Brachytherapy. 2014 May.12(5):457-462. Pubmedid: 23707855.
  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience. J Gastrointest Surg. 2014 Mar.18(3):505-511. Pubmedid: 24443204.
  • Latifi K, Dilling TJ, Hoffe SE, Stevens CW, Moros EG, Zhang GG. Evaluating Effects of Radiation Therapy Treatment on 4DCT-Calculated Lung Ventilation. Pract Radiat Oncol. 2014 Mar.3(2 Suppl 1):S6-S7. Pubmedid: 24674563.
  • Figura N, Latifi K, Dilling TJ, Kuykendall CC, Eikman EA, Moros EG, Zhang GG, Leuthold S, Mehra C, Hoffe SE. Dosimetric Implications of Treating 4D PET/CT-Defined Maximum Inhale Versus Exhale Target Volumes in Esophageal Cancer. Pract Radiat Oncol. 2014 Mar.3(2 Suppl 1):S34-S35. Pubmedid: 24674556.
  • Kuykendall CC, Budzevich MM, Latifi K, Moros EG, Hoffe SE, Dilling TJ, Zhang GG, Montilla-Soler JL, Eikman EA. 4D PET/CT: Radiology Imaging to Radiation Therapy. Pract Radiat Oncol. 2014 Mar.3(2 Suppl 1):S28. Pubmedid: 24674534.
  • Budzevich MM, Kuykendall CC, Latifi K, Oliver J, Dilling TJ, Hoffe SE, Eikman EA, Montilla-Soler JI, Zhang GG, Moros EG. A Method to Determine the Optimal Number of Bins in 4D PET. Pract Radiat Oncol. 2014 Mar.3(2 Suppl 1):S25. Pubmedid: 24674527.
  • Saeed N, Latifi K, Hoffe SE, Cruz A, Opp DW, Moros EG, Zhang GG, Budzevich MM, Shridhar R, Dilling TJ. Optimizing Options for Re-irradiation With Deformable Image Registration of Prior Plans. Pract Radiat Oncol. 2014 Mar.3(2 Suppl 1):S16-S17. Pubmedid: 24674497.
  • Fernandez DC, Hoffe SE, Barthel JS, Vignesh S, Klapman JB, Harris C, Almhanna K, Biagioli MC, Meredith KL, Feygelman V, Rao NG, Shridhar R. Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy. Pract Radiat Oncol. 2014 Mar.3(1):32-39. Pubmedid: 24674261.
  • Gwede CK, Vadaparampil ST, Hoffe S, Quinn GP. The role of radiation oncologists and discussion of fertility preservation in young cancer patients. Pract Radiat Oncol. 2014 Mar.2(4):242-247. Pubmedid: 24674159.
  • Oliver JA, Budzevich M, Zhang G, Moros EG, Latifi K, Kuykendall C, Hoffe S, Montilla-Soler J, Eikman E, Dilling T. Positron emission tomography texture analysis of necrosis in primary adenocarcinomas of the lung. Pract Radiat Oncol. 2014 Mar.3(2 Suppl 1):S29-S30. Pubmedid: 24674537.
  • Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug.57(8):941-957. Pubmedid: 25003289. Pmcid: PMC4100249.
  • Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer. 2014 Apr.120(8):1171-1177. Pubmedid: 24390779.
  • Hoffe S, Rao N, Shridhar R. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Semin Radiat Oncol. 2014 Apr.24(2):113-125. Pubmedid: 24635868.
  • Ashraf N, Hoffe S, Kim R. French FNCLCC/FFCD 9703 study. Oncologist. 2014 Apr.19(4):431. Pubmedid: 24729607. Pmcid: PMC3983828.
  • de la Fuente SG, Weber J, Hoffe SE, Shridhar R, Karl R, Meredith KL. Initial experience from a large referral center with robotic-assisted Ivor Lewis esophagogastrectomy for oncologic purposes. Surg Endosc. 2013 Sep.27(9):3339-3347. Pubmedid: 23549761.
  • Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013 Sep.20(9):3038-3043. Pubmedid: 23625142.
  • Wong J, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith KL. Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy. J Gastrointest Surg. 2013 Sep.17(9):1562-1568. Pubmedid: 23818125.
  • Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, Meredith KL. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 May.119(9):1636-1642. Pubmedid: 23361968.
  • Melis M, Weber J, Shridhar R, Hoffe S, Almhanna K, Karl RC, Meredith KL. Body mass index and perioperative complications after oesophagectomy for adenocarcinoma: a systematic database review. BMJ Open. 2013 May.3(5). Pubmedid: 23645908. Pmcid: PMC3646172.
  • Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013 Mar.31(7):886-894. Pubmedid: 23341531. Pmcid: PMC4820756.
  • Chuong MD, Freilich JM, Hoffe SE, Fulp W, Weber JM, Almhanna K, Dinwoodie W, Rao N, Meredith KL, Shridhar R. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointest Cancer Res. 2013 Mar.6(2):39-45. Pubmedid: 23745158. Pmcid: PMC3674462.
  • Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013 Jul.86(3):516-522. Pubmedid: 23562768.
  • Latifi K, Forster KM, Hoffe SE, Dilling TJ, Dekker A, Van Elmpt W, Zhang GG. Dependence of ventilation image derived from 4D CT on deformable image registration and ventilation algorithms. J Appl Clin Med Phys. 2013 Jul.14(4):4247. Pubmedid: 23835389. Pmcid: PMC5714535.
  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Prognostic impact of lymph node retrieval and ratio in gastric cancer: a U.S. single center experience. J Gastrointest Surg. 2013 Dec.17(12):2059-2066. Pubmedid: 24129828.
  • Pimiento JM, Weber J, Hoffe SE, Shridhar R, Almhanna K, Vignesh S, Karl RC, Meredith KL. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013 Aug.20(8):2706-2712. Pubmedid: 23504118.
  • Hernandez JM, Dimou F, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith K. Defining the learning curve for robotic-assisted esophagogastrectomy. J Gastrointest Surg. 2013 Aug.17(8):1346-1351. Pubmedid: 23690208.
  • Shridhar R, Weber J, Hoffe SE, Almhanna K, Karl R, Meredith K. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis. J Gastrointest Surg. 2013 Aug.17(8):1339-1345. Pubmedid: 23749498.
  • Vignesh S, Hoffe SE, Meredith KL, Shridhar R, Almhanna K, Gupta AK. Endoscopic therapy of neoplasia related to Barrett's esophagus and endoscopic palliation of esophageal cancer. Cancer Control. 2013 Apr.20(2):117-129. Pubmedid: 23571702.
  • Almhanna K, Meredith KL, Hoffe SE, Shridhar R, Coppola D. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Control. 2013 Apr.20(2):111-116. Pubmedid: 23571701.
  • Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, Hoffe SE. Radiation therapy and esophageal cancer. Cancer Control. 2013 Apr.20(2):97-110. Pubmedid: 23571700.
  • Wong JY, Shridhar R, Almhanna K, Hoffe SE, Karl RC, Meredith KL. The impact of body mass index on esophageal cancer. Cancer Control. 2013 Apr.20(2):138-143. Pubmedid: 23571704.
  • Javedan K, Zhang GG, Hoffe S, Feygelman V, Forster K. Comparing dose in the build-up region between compensator- and MLC-based IMRT. J Appl Clin Med Phys. 2012 Sep.13(5):3748. Pubmedid: 22955641. Pmcid: PMC5718229.
  • Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012 May.19(5):1678-1684. Pubmedid: 22045465.
  • Mathew BM, Daas AY, Centeno BA, Hoffe S, Valone T, Patel M, Springett GM. Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma. Clin Adv Hematol Oncol. 2012 May.10(5):340-343. Pubmedid: 22706548.
  • Shridhar R, Dombi GW, Weber J, Hoffe SE, Meredith K, Konski A. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis. Am J Clin Oncol. 2012 Jun.35(3):216-221. Pubmedid: 21378540.
  • Latifi K, Dilling T, Hoffe S, Stevens C, Moros E, Zhang G. SU-E-J-187: Evaluation of the Effects of Dose on 4DCT-Calculated Lung Ventilation. Med Phys. 2012 Jun.39(6Part9):3695-3696. Pubmedid: 28519064.
  • Shridhar R, Hayman T, Hoffe SE, Weber J, Almhanna K, Chuong M, Karl RC, Meredith KL. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy. J Gastrointest Surg. 2012 Jul.16(7):1296-1302. Pubmedid: 22399271.
  • Robinson J, Opp D, Zhang G, Cashon K, Kozelka J, Hunt D, Walker L, Hoffe S, Shridhar R, Feygelman V. Evaluating dosimetric accuracy of flattening filter free compensator-based IMRT: measurements with diode arrays. Med Phys. 2012 Jan.39(1):342-352. Pubmedid: 22225304.
  • Hoffe S, Balducci L. Cancer and age: general considerations. Clin Geriatr Med. 2012 Feb.28(1):1-18. Pubmedid: 22326032.
  • Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, Wilson GD. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2012 Apr.2011:439752. Pubmedid: 22162711. Pmcid: PMC3227385.
  • Yu HH, Hoffe SE. Beyond the conventional role of external-beam radiation therapy for skeletal metastases: new technologies and stereotactic directions. Cancer Control. 2012 Apr.19(2):129-136. Pubmedid: 22487975.
  • Yu HH, Tsai YY, Hoffe SE. Overview of diagnosis and management of metastatic disease to bone. Cancer Control. 2012 Apr.19(2):84-91. Pubmedid: 22487970.
  • Shridhar R, Dombi GW, Finkelstein SE, Meredith KL, Hoffe SE. Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2011 Sep.117(17):3908-3916. Pubmedid: 21365627.
  • Melis M, Weber JM, McLoughlin JM, Siegel EM, Hoffe S, Shridhar R, Turaga KK, Dittrick G, Dean EM, Karl RC, Meredith KL. An elevated body mass index does not reduce survival after esophagectomy for cancer. Ann Surg Oncol. 2011 Mar.18(3):824-831. Pubmedid: 20865331. Pmcid: PMC4623586.
  • Vignesh S, Hoffe SE, Saif MW. EUS-guided pancreatic diagnosis and beyond. Highlights from the "2011 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. January 20-22, 2011. JOP. 2011 Mar.12(2):86-91. Pubmedid: 21386627.
  • Zhang G, Feygelman V, Stevens C, Li W, Leuthold S, Springett G, Hoffe S. Re-planning for compensator-based IMRT with original compensators. Med Dosim. 2011 Jun.36(1):102-108. Pubmedid: 20207532.
  • Barthel JS, Kucera S, Harris C, Canchi D, Hoffe S, Meredith K. Cryoablation of persistent Barrett's epithelium after definitive chemoradiation therapy for esophageal adenocarcinoma. Gastrointest Endosc. 2011 Jul.74(1):51-57. Pubmedid: 21549371.
  • Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Gastrointest Cancer Res. 2011 Jul.4(4):128-134. Pubmedid: 22368736. Pmcid: PMC3283109.
  • Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011 Aug.104(2):155-161. Pubmedid: 21520097. Pmcid: PMC3347705.
  • McLean K, Lilienfeld H, Caracciolo JT, Hoffe S, Tourtelot JB, Carter WB. Management of isolated Adrenal Lesions in Cancer Patients. Cancer Control. 2011 Apr.18(2):113-126. Pubmedid: 21451454.
  • Biagioli MC, Hoffe SE. Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window. Cancer Control. 2010 Oct.17(4):223-232. Pubmedid: 20861810.
  • Hoffe SE, Shridhar R, Biagioli MC. Radiation therapy for rectal cancer: current status and future directions. Cancer Control. 2010 Jan.17(1):25-34. Pubmedid: 20010516.
  • Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control. 2010 Jan.17(1):44-51. Pubmedid: 20010518.
  • Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?. Gastrointest Endosc. 2010 Feb.71(2):235-240. Pubmedid: 20003971.
  • Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010 Apr.17(4):1159-1167. Pubmedid: 20140529.
  • Hoffe SE, Finkelstein SE, Russell MS, Shridhar R. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control. 2010 Apr.17(2):100-110. Pubmedid: 20404793.
  • Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control. 2008 Oct.15(4):295-307. Pubmedid: 18813197.
  • Dilling TJ, Hoffe SE. Stereotactic body radiation therapy: transcending the conventional to improve outcomes. Cancer Control. 2008 Apr.15(2):104-111. Pubmedid: 18376377.
  • Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology. 2007 Sep.85(4):216-220. Pubmedid: 17541257.
  • Strosberg J, Hoffe S, Hazelton T, Kvols L. External beam irradiation of myocardial carcinoid metastases: a case report. J Med Case Rep. 2007 Sep.1:95. Pubmedid: 17880715. Pmcid: PMC2040153.
  • Venkat PS, Hoffe SE, Frakes JM. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 24(3):1073274817729259. Pubmedid: 28975831. Pmcid: PMC5937228.
  • Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience. Cancer Control. 24(5):1073274817729076. Pubmedid: 28975822. Pmcid: PMC5937248.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

119 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments